ClinicalTrials.gg
CompletedNCT00042081Updated May 5, 2006

Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures

A Phase 3 interventional study of CGT003 (E2F Duplex Decoy) in Coronary Artery Disease, sponsored by Anesiva, Inc.. Completed at 154 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2006-05-05.

Sponsored by Anesiva, Inc. · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,104 studies in Coronary Artery Disease with a site in United States — 99 open to participants now, 144 under way, 10 of them phase 3. Coronary Artery Disease · United States.

Enrollment
40th of 745
3,000 · median 107
Started
2002
with 18 others
Phase 3
101 of 1,104
4 open now
Registered
20th of 1,104
by date

Among the 1,104 studies in Coronary Artery Disease with a site in United States, this one is the 40th largest by enrollment of the 745 interventional ones that give a count, is one of 19 that started in 2002, is one of 101 in phase 3, and was the 20th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

99 of the 1,104 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,104 studies in Coronary Artery Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass surgery.

Read the detailed description

Coronary vascular disease manifested by narrowing of the coronary arteries is one of the more common manifestations of atherosclerotic vascular disease. The clinical manifestations of coronary artery disease include death, angina pectoris, myocardial infarction, congestive heart failure and arrhythmia. Restoration of circulation to the heart may be undertaken using a variety of techniques including angioplasty, stenting, and bypass grafting.

Approximately 359,000 patients underwent coronary bypass procedures in the U.S. in 1999. Long term studies have observed an incidence of vein graft occlusion at 19% at 1 year, 25% at 5 years and 50% by 15 years after operation for an overall rate of 2.5% per year after the first year of observation. The consequences of graft failure are as significant as those of primary atherosclerotic disease and include ischemia, myocardial infarction and death.

CGT003 is a novel therapeutic that is under investigation as a treatment to prevent vein graft failure. It acts by inhibiting the transcription factor, E2F, which is activated in response to injury such as that which occurs when thin-walled vein grafts are exposed to the pressures of the arterial circulation. Blockade of E2F inhibits smooth muscle cell proliferation and redirects the vein graft remodeling that occurs within the first several days after implantation towards medial hypertrophy and strengthening of the medial layer and blunts formation of neointima. Inhibition of neotinimal formation coupled with expansion of the media should result in a decreased risk of the accelerated atherosclerosis and consequent vein graft failure over several years.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • CABG
  • coronary artery bypass surgery
  • coronary artery disease
  • coronary arteriosclerosis
  • coronary stenosis
  • coronary occlusion
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

PATIENTS MUST:

  • Have coronary artery disease and be scheduled to undergo a coronary artery bypass (CABG) procedure that is to include at least two segments of autogenous vein (sequential grafts do not count as two separate grafts).
  • Be between 18 and 80 years old.
  • Have a documented negative serum pregnancy test for all women of .
  • Be using an acceptable method of if of .
  • Have agreed to participate voluntarily and signed and dated an IRB-approved, Patient form.
  • (If one of the first 2400 patients enrolled) have agreed to participate voluntarily and signed and dated an IRB-approved, Patient Informed Consent form for the Angiography population.
  • Note: Patients who are to receive an arterial bypass to the left anterior descending artery in addition to the two vein grafts required by the protocol ARE eligible for this study.
  • Note: Patients ARE eligible for enrollment regardless of whether the planned procedure is to be on or off cardiopulmonary bypass pump.
  • Note: Patients who do not wish to undergo elective Angiography at one year SHOULD NOT be enrolled in the first 2400 patients.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
3,000 participants

Interventions

  • DrugCGT003 (E2F Duplex Decoy)
06

Study locations

154 sites
  • Brookwood Medical Center
    Birmingham, Alabama 35209, United States
  • Cardio-Thoracic Surgeons, P.C.
    Birmingham, Alabama 35209, United States
  • Baptist Medical Center - Montclair
    Birmingham, Alabama 35213, United States
  • Cardio-Thoracic Surgeons, P.C.
    Birmingham, Alabama 35213, United States
  • Cardio-Thoracic Surgeons, P.C.
    Birmingham, Alabama 35235, United States
  • Medical Center East
    Birmingham, Alabama 35235, United States
  • Seton Medical Center
    Daly City, California 94015, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Desert Regional Medical Center
    Palm Springs, California 92262, United States
  • St. Joseph's Medical Center
    Stockton, California 95204, United States
  • St. Vincent's Medical Center
    Bridgeport, Connecticut 06606, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Florida Cardiovascular Research
    Atlantis, Florida 33462, United States
  • JFK Medical Center
    Atlantis, Florida 33462, United States
  • Morton Plant Hospital
    Clearwater, Florida 33756, United States
  • Holmes Regional Medical Center
    Melbourne, Florida 32901, United States
  • Cardiovascular Surgeons, P.A.
    Orlando, Florida 32801, United States
  • Florida Hospital
    Orlando, Florida 32803, United States
  • Orlando Cardiovascular Center, LLLP
    Orlando, Florida 32806, United States
  • Orlando Heart Center
    Orlando, Florida 32806, United States
  • Orlando Regional Med Center
    Orlando, Florida 32806, United States
  • Orlando Heart Center/Sand Lake
    Orlando, Florida 32819, United States
  • Clinical Research Center
    Sarasota, Florida 34239, United States
  • Sarasota Memorial Health Care System
    Sarasota, Florida 34239, United States
  • Crawford Long Hospital
    Atlanta, Georgia 30308, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • St. Elizabeth's Hospital
    Belleville, Illinois 62220, United States
  • Memorial Hospital
    Belleville, Illinois 62226, United States
  • Northwestern Medical Facility Foundation
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Rush Presbyterian St. Luke's Medical Center
    Chicago, Illinois 60612, United States
  • Rush Professional Building
    Chicago, Illinois 60612, United States
  • Resurrection Medical Center
    Chicago, Illinois 60631, United States
  • Evanston Northwestern Healthcare, Highland Park Hospital
    Evanston, Illinois 60201, United States
  • Evanston Northwestern Healthcare
    Evanston, Illinois 60201, United States
  • St. Francis Hospital of Evanston
    Evanston, Illinois 60202, United States
  • Loyola University Chicago Medical Center
    Maywood, Illinois 60153, United States
  • Edward Hospital & Health Services
    Naperville, Illinois 60540, United States
  • Advocate Christ Hospital and Medical Center
    Oak Lawn, Illinois 60453, United States
  • OSF St. Francis Medical Center
    Peoria, Illinois 61637, United States
  • Memorial Medical Center
    Springfield, Illinois 62702, United States
  • Southern Illinois University School of Medicine, Dep. of Surgery, Div. of Cardiothoracic Surgery
    Springfield, Illinois 62702, United States
  • Southern Illinois University School of Medicine, Department of Surgery, Division of Cardiothoracic Surgery
    Springfield, Illinois 62702, United States
  • St. John's Hospital
    Springfield, Illinois 62702, United States
  • Central DuPage Hospital
    Winfield, Illinois 60190, United States
  • St. Vincent Hospital and Health Care Service
    Indianapolis, Indiana 46260, United States
  • The Heart Center of Indiana
    Indianapolis, Indiana 46290, United States
  • Genesis Heart Institute
    Davenport, Iowa 52803, United States
  • Genesis Medical Center
    Davenport, Iowa 52803, United States
  • Iowa Methodist Medical Center
    Des Moines, Iowa 50309, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Georgetown Professional Plaza
    Overland Park, Kansas 66204, United States
  • Shawnee Mission Medical Center
    Shawnee Mission, Kansas 66204, United States
  • Jewish Hospital Health Care Services
    Louisville, Kentucky 40202, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Cardiac Surgery Associates
    Baltimore, Maryland 21215, United States
  • Sinai Hospital of Baltimore
    Baltimore, Maryland 21215, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Peninsula Regional Medical Center
    Salisbury, Maryland 21801, United States
  • Washington Adventist Hospital
    Takoma Park, Maryland 20912, United States
  • Cardiac Surgery Associates
    Towson, Maryland 21204, United States
  • Midatlantic Cardiovascular Associates, P.A.
    Towson, Maryland 21204, United States
  • St. Joseph Medical Center
    Towson, Maryland 21204, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • McLaren Regional Medical Center
    Flint, Michigan 48532, United States
  • Spectrum Health Hospitals
    Grand Rapids, Michigan 49503, United States
  • Ingham Regional Medical Center
    Lansing, Michigan 48910, United States
  • Thoracic & Cardiovascular Healthcare Foundation
    Lansing, Michigan 48910, United States
  • Thoracic & Cardiovascular Institute
    Lansing, Michigan 48910, United States
  • Cardiology Consultants, PC
    Petoskey, Michigan 49770, United States
  • Great Lakes Cardiothoracic and Vascular Surgery
    Petoskey, Michigan 49770, United States
  • Northern Michigan Hospital
    Petoskey, Michigan 49770, United States
  • Petoskey Cardiology
    Petoskey, Michigan 49770, United States
  • Michigan Cardiovascular Institute
    Saginaw, Michigan 48601, United States
  • Convenant Medical Center
    Saginaw, Michigan 48602, United States
  • St. Mary's/Duluth Clinic Health System
    Duluth, Minnesota 55805, United States
  • Abbott Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
  • Park Nicollet Institute
    Minneapolis, Minnesota 55416, United States
  • Methodist Hospital
    St. Louis Park, Minnesota 55426, United States
  • Park Nicollet Heart Center
    St. Louis Park, Minnesota 55426, United States
  • Forrest General Hospital
    Hattiesburg, Mississippi 39401, United States
  • St. John's Regional Medical Center
    Joplin, Missouri 64804, United States
  • 930 Carondelet Drive
    Kansas City, Missouri 64114, United States
  • Missouri Baptist Medical Center
    St. Louis, Missouri 63131, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • Nebraska Heart Institute
    Omaha, Nebraska 68131, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68131, United States
  • Nebraska Heart Institute
    Papillion, Nebraska 68046, United States
  • Morristown Memorial Hospital
    Morristown, New Jersey 07962, United States
  • Robert Wood Johnson University Hospital
    New Brunswick, New Jersey 08903, United States
  • Umdnj-Rwjms
    New Brunswick, New Jersey 08903, United States
  • The Valley Hospital
    Ridgewood, New Jersey 07450, United States
  • Lenox Hill Hospital
    New York, New York 10021, United States
  • New York Presbyterian Medical Center, Milstein Hospital Building
    New York, New York 10032, United States
  • Westchester Medical Center
    Valhalla, New York 10595, United States
  • University of North Carolina Hospitals
    Chapel Hill, North Carolina 27154, United States
  • Ambulatory Care Center
    Chapel Hill, North Carolina 27514, United States

Showing the first 100 of 154 sites. Choose a country and city above to see the rest.

07

References and documents

Publications

  • Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2446-54. doi: 10.1001/jama.294.19.2446. PubMed 16287955 ↗
  • Harskamp RE, Alexander JH, Ferguson TB Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, Gibson CM, Peterson ED, Harrington RA, Smith PK, Lopes RD. Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. Circulation. 2016 Jan 12;133(2):131-8. doi: 10.1161/CIRCULATIONAHA.115.015549. Epub 2015 Dec 8. PubMed 26647082 ↗
  • Hess CN, Lopes RD, Gibson CM, Hager R, Wojdyla DM, Englum BR, Mack MJ, Califf RM, Kouchoukos NT, Peterson ED, Alexander JH. Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. Circulation. 2014 Oct 21;130(17):1445-51. doi: 10.1161/CIRCULATIONAHA.113.008193. Epub 2014 Sep 26. PubMed 25261549 ↗
  • Harskamp RE, Alexander JH, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, Gibson CM, Califf RM, Kouchoukos NT, Harrington RA, Ferguson TB Jr, Lopes RD. Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. JAMA Surg. 2014 Aug;149(8):798-805. doi: 10.1001/jamasurg.2014.87. Erratum In: JAMA Surg. 2014 Sep;149(9):961. PubMed 25073921 ↗
  • Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH. Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J. 2012 Sep;164(3):379-386.e1. doi: 10.1016/j.ahj.2012.05.019. PubMed 22980305 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2002
First posted
Jul 24, 2002
Start
Jul 2002
Completion
Feb 2005
Last update
May 5, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on May 5, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00042081
Lead sponsor
Anesiva, Inc.
First posted
Jul 24, 2002
Start date
Jul 2002
Completion
Feb 2005
Last update
May 5, 2006

Study contacts

Todd Lorenz, M.D.
study director · Anesiva, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion